EGFR Mutant NSCLC and Platinum Resistant Ovarian Cancer
1 clinical trials · Condition
◉ Watch EGFR Mutant NSCLC and Platinum Resistant Ovarian Cancer
| Record | Firm | Date |
|---|---|---|
| A Study of IBI363 Combination Therapy in Participants With Advanced Solid Tumors (NCT07124793) | Innovent Biologics (Suzhou) Co. Ltd. | 2025-08-31 |
Track EGFR Mutant NSCLC and Platinum Resistant Ovarian Cancer automatically
Every clearance here is in the API, with alerts when new ones post.